Please ensure Javascript is enabled for purposes of website accessibility

Better Dividend Stock to Buy: AbbVie Inc. vs. Pfizer Inc.

By Cory Renauer – Apr 3, 2018 at 8:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Both of these big pharma stocks pay a nice dividend yield, but which is the better pick right now?

Big dividends are getting hard to find, but a couple pharma stocks are offering juicy yields at recent prices. Shares of Pfizer Inc. (PFE -0.91%) pay a nice 3.8%, and AbbVie Inc. (ABBV -5.96%) looks even more tempting with a 4.1% yield at recent prices. 

A larger dividend up front won't help you if it doesn't grow, and both of these companies face challenges ahead that could make steady payout bumps difficult or even impossible. Exciting new drugs in development could save the day and keep the distributions growing steadily. Let's stack the pair side by side to see which has a better chance of coming out ahead.

Person weighing two dollar signs with their hands.

Image source: Getty Images.

In the numbers

America's largest pharmaceutical company offers a nice yield now, but its history isn't too reassuring. It's only been about nine years since generic competition for blockbuster drugs forced Pfizer to slash its payout. Also, the company has steadily raised its dividend at a respectable 7.8% annual rate over the past five years, making this year's 6.3% bump a bit of a letdown.

Company Latest Dividend Bump Total Share Repurchase Authority Repurchase Authority as a Percentage of Market Cap
AbbVie Inc. 35% $10 billion 7%
Pfizer Inc. 6% $16 billion 8%

Data source: Company SEC filings.

Rather than commit to a dividend that could be difficult to maintain during an uncertain future, Pfizer beefed up its share repurchase program. AbbVie's share repurchase program is a step behind Pfizer's, but its distribution's grown by leaps and bounds since the company's 2013 debut.

Pfizer expects total revenue to rise just 4% this year, but buybacks will help adjusted earnings grow 11% in 2017 to $2.65 per share, which is the same pace earnings rose last year. With an annualized payout of just $1.36 per share, Pfizer has a lot of room to make big increases even if earnings hit the low end of its guided range for 2018: $2.90 per share. 

This impressive performance pales in comparison to AbbVie's. The company raised adjusted earnings 16% to $5.60 last year and management expects a huge jump to $7.33 per share this year. With its dividend at an annualized $3.84 per share, AbbVie can probably afford to make some more sizable payout bumps in the years ahead.

Going down

Pfizer claims that generic competition following patent expirations for various products led to $2.1 billion in lost revenue last year. Teva launched a generic version of Viagra in December and Lyrica could become vulnerable this December. From this year forward, generic competition around the globe will impact products that were responsible for around 14% of last year's total revenue.

The main patent guarding Humira, the drug responsible for around two-thirds of AbbVie's total revenue, expired last year. A deal with Amgen (AMGN -1.32%) will keep its biosimilar from entering the U.S. market until 2023. The Food and Drug Administration has approved a second copycat competitor from Boehringer Ingelheim, but it's tied up in the courts as well.

Although Humira could become a $21 billion drug in 2020, eventually it will leave a gaping hole in the company's income statement. Luckily, AbbVie has promising younger products on the field and warming up the bench.

Person looking out a window at three upward sloping charts.

Image source: Getty Images.

On the way up

Not long before its most expensive pipeline asset flopped, the company predicted non-Humira sales would rise from $9.8 billion last year to more than $35 billion by 2025. Despite Rova-T's disappointment, AbbVie has three drugs in late-stage development that could generate a combined $12 billion several years down the road from now if approved. 

AbbVie doesn't need to wait for FDA approvals to reduce its reliance on Humira. The company's share of sales from a leukemia pill called Imbruvica rose 41% to $2.1 billion in 2017 and could double again in a few more years. 

Pfizer also owes a great deal of its recent success to a more recently launched cancer treatment called Ibrance. During breast cancer trials that led to its approval, Ibrance reduced the risk of disease progression by 42% for the genetically defined group of breast cancer patients it's approved to treat. With this in mind, you can see why sales of the tablets soared to $3.1 billion in 2017, its second full year post-approval.

While Ibrance marches higher, Pfizer's late-stage pipeline is getting set to deliver. An experimental breast cancer tablet it acquired in 2015 helped reduce the risk of disease progression by 46% for a much larger cross-section of patients than Ibrance is cleared to treat. Pfizer hasn't sent an application for talazoparib to the FDA yet, but I expect it to outperform Ibrance if approved.

The better dividend stock to buy now?

Choosing a winner isn't easy, and if it weren't for the dismal state of biosimilar competition, my choice would be different. From the same starting point, it looks like AbbVie can deliver more dividend income over the long run but only if Humira sales keep growing for a few more years then trail off slowly. Given the company's ability to force a heavy hitter like Amgen to settle for a delayed launch, I'd say the odds are good enough to call it a winner today.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$134.21 (-5.96%) $-8.51
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$43.76 (-0.91%) $0.40
Amgen Inc. Stock Quote
Amgen Inc.
AMGN
$225.40 (-1.32%) $-3.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
104%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.